When meeting with Rep. Earl Blumenauer (D-OR), Ms. Blank and ACP Resident/Fellow Member Joel Burnett, MD, led discussions on prescription drug pricing and physician workforce issues. ... I don't have any problems with that,” although the downside is
Caleb Alexander, MD, co-director of the Johns Hopkins School of Public Health Center for Drug Safety and Effectiveness in Baltimore. ... educated about the risks and benefits and if you can effectively monitor for safety.
But at this point, he noted, the drug remains costly for many patients. ... Food and Drug Administration. FDA Drug Safety Communication: Safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate
Photo by ThinkStock. A drug safety communication that canagliflozin (Invokana, Invokamet) causes an increased risk of leg and foot amputations. ... A drug safety communication about gadolinium-based contrast agents for MRI. An FDA review, initiated in
A drug safety communication that hepatitis C medicines have led to rare cases of worsening liver function or liver failure in some patients. ... The drug was originally approved in 2014 to treat adults with idiopathic pulmonary fibrosis.